SCLC
Clinical trials for SCLC explained in plain language.
Never miss a new study
Get alerted when new SCLC trials appear
Sign up with your email to follow new studies for SCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation approach aims to spare brain cancer patients from treatment side effects
Disease control Recruiting nowThis study compares two radiation methods for patients whose cancer has spread to the brain and who are receiving immunotherapy. Researchers want to see if spreading radiation over several days causes fewer side effects than giving it all at once. The trial will enroll 244 adults…
Matched conditions: SCLC
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New cancer drug trial seeks to control advanced tumors
Disease control Recruiting nowThis study is testing a new drug, TUB-030, to see if it is safe and can help control advanced solid cancers in adults. Researchers will give the drug every three weeks to find the highest dose patients can tolerate. They will also look for early signs that the drug might work, es…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation
Disease control Recruiting nowThis study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Real-World check on promising lung cancer drug
Disease control Recruiting nowThis study aims to see how well the drug Zepzelca works and how safe it is for patients with advanced small cell lung cancer in everyday medical practice. It will observe about 300 patients whose cancer has spread and who have already tried standard chemotherapy. The main goal is…
Matched conditions: SCLC
Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for cancers that resist standard treatments
Disease control Recruiting nowThis study is testing whether combining two drugs can help people with aggressive cancers that have stopped responding to standard treatments. It focuses on small cell lung cancer and other cancers with specific genetic weaknesses that have become resistant to previous drugs. The…
Matched conditions: SCLC
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo tested to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to…
Matched conditions: SCLC
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope drug enters human testing for ten types of advanced cancer
Disease control Recruiting nowThis is the first human study of an experimental drug called SLV-154 for people with advanced solid tumors that have spread. The main goal is to find the highest safe dose and understand how the body processes the drug. About 70 adults with one of ten specific advanced cancers wh…
Matched conditions: SCLC
Phase: PHASE1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC